Complementary Mechanisms of Angiotensin Receptor Blockers and Calcium Channel Blockers in Managing Hypertension

References

• . Chobanian AV, Bakris GL, Black HR,; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252
   PubMed Web of Science ®Google Scholar
• . Mancia G, De Backer G, Dominiczak A,. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462–1536
   PubMed Web of Science ®Google Scholar
• . Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983–1992
   PubMed Web of Science ®Google Scholar
• . Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427
   PubMed Web of Science ®Google Scholar
• . Smith DH. Fixed-dose combination antihypertensives and reduction in target organ damage: are they all the same? Am J Cardiovasc Drugs. 2007;7(6):413–422
   PubMed Web of Science ®Google Scholar
• . Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–719
   PubMed Web of Science ®Google Scholar
• . Padilla MC, Armas-Hernández MJ, Hernández RH, Israili ZH, Valasco M. Update of diuretics in the treatment of hypertension. Am J Ther. 2007;14(2):154–160
   PubMedGoogle Scholar
• . Dahlof B, Sever PS, Poulter NR,; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906
   PubMed Web of Science ®Google Scholar
• . Mason JM, Dickinson HO, Nicolson DJ, Campbell F, Ford GA, Williams B. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens. 2005;23(10):1777–1781
   PubMed Web of Science ®Google Scholar
• . Wiysonge CS, Bradley H, Mayosi BM,. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007(1):CD002003
   Google Scholar
• . Beevers DG. The end of beta blockers for uncomplicated hypertension? Lancet. 2005;366(9496):1510–1512
   PubMedGoogle Scholar
• . Norris K, Neutel JM. Emerging insights in the first-step use of antihypertensive combination therapy. J Clin Hypertens (Greenwich). 2007;9(12 suppl 5):5–14
   PubMedGoogle Scholar
• . White WB. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension. Blood Press Monit. 2008;13(2):123–129
   PubMedGoogle Scholar
• . Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens. 2004;17(3):252–259
   PubMed Web of Science ®Google Scholar
• . Haller H. Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk. Int J Clin Pract. 2008;62(5):781–790
   PubMedGoogle Scholar
• . Mancia G. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol. 2005;42( suppl 1):S17–S25
   PubMed Web of Science ®Google Scholar
• . Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab. 2004;30(6):487–496
   PubMed Web of Science ®Google Scholar
• . Aguilar D, Solomon SD. ACE inhibitors and angiotensin receptor antagonists and the incidence of new-onset diabetes mellitus: an emerging theme. Drugs. 2006;66(9):1169–1177
   PubMedGoogle Scholar
• . Guazzi MD, De Cesare N, Galli C,. Calcium-channel blockade with nifedipine and angiotensin converting-enzyme inhibition with captopril in the therapy of patients with severe primary hypertension. Circulation. 1984;70(2):279–284
   PubMed Web of Science ®Google Scholar
• . Jamerson K, Weber MA, Bakris GL,; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–2428
   PubMed Web of Science ®Google Scholar
• . Bakris GL. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich). 2008;10(1 suppl 1):27–32
   PubMed Web of Science ®Google Scholar
• . Plosker GL, Robinson DM. Amlodipine/valsartan: fixed-dose combination in hypertension. Drugs. 2008;68(3):373–381
   PubMed Web of Science ®Google Scholar
• . Philipp T, Smith TR, Glazer R,. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29(4):563–580
   PubMed Web of Science ®Google Scholar
• . Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30(4):587–604
   PubMed Web of Science ®Google Scholar
• . Dahlöf B, Devereux RB, Kjeldsen SE,. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003
   PubMed Web of Science ®Google Scholar
• . Julius S, Kjeldsen SE, Weber M,; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022–2031
   PubMed Web of Science ®Google Scholar
• . Goodfriend TL. Angiotensins: actions and receptors. In: Izzo JL Jr, Black HR, Goodfriend TL, eds. Hypertension Primer: The Essentials of High Blood Pressure. 3rd ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2003;8–11
   Google Scholar
• . Mire DE, Silfani TN, Pugsley MK. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol. 2005;46(5):585–593
   PubMed Web of Science ®Google Scholar
• . Weber MA. Angiotensin II receptor blockers. In: Izzo JL Jr, Black HR, Goodfriend TL, eds. Hypertension Primer: The Essentials of High Blood Pressure. 3rd ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2003;430–432
   Google Scholar
• . Carey RM, Wang ZQ, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension. 2000;35(1 pt 2):155–163
   PubMed Web of Science ®Google Scholar
• . Weir MR, Izzo JL Jr. Calcium antagonists. In: Izzo JL Jr, Black HR, Goodfriend TL, eds. Hypertension Primer, The Essentials of High Blood Pressure. 3rd ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2003;433–437
   Google Scholar
• . Basile J. The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens (Greenwich). 2004;6(11):621–629
   PubMedGoogle Scholar
• . Mizuno Y, Jacob RF, Mason RP. Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease. Am J Hypertens. 2008;21(10):1076–1085
   PubMedGoogle Scholar
• . Siragy HM, Xue C, Webb RL. Beneficial effects of combined benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-alpha production after cardiac ischemia. J Cardiovasc Pharmacol. 2006;47(5):636–642
   PubMed Web of Science ®Google Scholar
• . Neutel JM, Smith DH, Weber MA, Schofield L, Purkayastha D, Gatlin M. Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. J Clin Hypertens (Greenwich). 2005;7(11):641–646
   PubMedGoogle Scholar
• . Morgan T, Anderson A. A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension. Am J Hypertens. 2002;15(6):544–549
   PubMedGoogle Scholar
• . Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129( suppl 1):169S–173S
   PubMed Web of Science ®Google Scholar
• . Kohlmann O Jr, Oigman W, Mion D Jr,. [The “LOTHAR” study: evaluation of efficacy and tolerability of the fixed combination of amlodipine and losartan in the treatment of essential hypertension]. Arq Bras Cardiol. 2006;86(1):39–51
   PubMedGoogle Scholar
• . Canzanello VJ, Baranco-Pryor E, Rahbari-Oskoui F,. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens. 2008; 21(1):61–66
   PubMed Web of Science ®Google Scholar
• . Kereiakes DJ, Neutel JM, Punzi HA, Xu J, Lipka LJ, Dubiel R. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am J Cardiovasc Drugs. 2007;7(5):361–372
   PubMed Web of Science ®Google Scholar
• . Minami J, Ishimitsu T, Matsuoka H. Pretreatment plasma renin activity levels correlate with the blood pressure response to telmisartan in essential hypertension. Am J Hypertens. 2008;21(1):10–13
   PubMedGoogle Scholar
• . Neutel JM, Smith DH, Silfani TN, Lee Y, Weber MA. Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. J Hum Hypertens. 2006;20(4):255–262
   PubMed Web of Science ®Google Scholar
• . Destro M, Luckow A, Samson M, Kandra A, Brunel P. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized double-blind, multicenter study: the EX-EFFeCTS Study. J Am Soc Hypertens. 2008;2(4):294–302
   PubMedGoogle Scholar
• . Schrader J, Salvetti A, Calvo C,. The combination of amlodipine/ valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. Int J Clin Pract. 2009;63(2):217–225
   PubMed Web of Science ®Google Scholar
• . Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001;3(5):283–291, 318
   PubMedGoogle Scholar
• . Oparil S, Silfani TN, Walker JF. Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am J Hypertens. 2005;18(2 pt 1):287–294
   PubMedGoogle Scholar
• . Giles TD, Oparil S, Silfani TN, Wang A, Walker JF. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich). 2007;9(3):187–195
   PubMedGoogle Scholar
• . Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs. 2008;68(9):1207–1225
   PubMed Web of Science ®Google Scholar
• . Krum H. Critical assessment of calcium antagonists. Aust Fam Physician. 1997;26(7):841–845, 847–848
   PubMedGoogle Scholar
• . Ofili EO. Dispelling the myth of “aggressive” antihypertensive therapy. J Clin Hypertens (Greenwich). 2006;8(1 suppl 1):4–11
   PubMedGoogle Scholar